Optimal Medical Therapy – Ventricular Assist Device other research project

Optimal Medical Therapy – Ventricular Assist Device other research project - OMT-VAD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00018074

Enrollment

250

Registered

2019-11-12

Start date

2018-04-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure I50

Interventions

Group 1: Patients who have had an LVAD (Left ventricular assist device) implanted at the German Heart Center Berlin between 2017 and 2019 and who are being treated for heart failure according to the c

Eligibility

Sex/Gender

All

Age

0 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients who received LVAD implant at the German Heart Center Berlin between 2015 and 2019.

Exclusion criteria

Exclusion criteria: Patients who didn’t survive LVAD implantation until discharge.

Design outcomes

Primary

Measure	Time frame
Purely descriptive analysis of patient data after adaptation of SOP.	—

Secondary

Measure	Time frame
Influence of drug therapy after a period of three, six and twelve months on quality of life, state of health, morbidity, complications of Ventricular Assist Device therapy and mortality of patients. Comparison of these points with a historical control group. ->Euro-Quality-of-Life-5-Dimensions-Questionnaire, Rockwood Scale, Six-minute walking test, Medication, Heart failure medication with side effects, Lab (Hemoglobin, Hematocrit, Internatinal Normalized Ratio, Gamma-glutamyltransferase, Lactate dehydrogenase, C-reactive protein, Blood urea nitrogen, Creatinine, Glomerular filtration rate, Dialyse, Albumin, Total bilirubin, N-terminal pro brain natriuretic peptide, Potassium) Echocardiographie (left ventricular ejection fraction, left ventricular enddiastolic volume, left ventricular enddiastolic diameter, right ventricular ejection fraction, right ventricular enddiastolic diameter, tricuspid annular plane systolic excursion, right ventricular outflow tract, aortic valve insufficiency, mitral valve insufficiency, pulmonary valve insufficiency, tricuspid valve insufficiency, systolic pulmonary arterial pressure) Rehospitalization, Pump Parameter, Mean arterial pressure, Heart frequency, Weight	—

Measure

Time frame

Influence of drug therapy after a period of three, six and twelve months on quality of life, state of health, morbidity, complications of Ventricular Assist Device therapy and mortality of patients. Comparison of these points with a historical control group. ->Euro-Quality-of-Life-5-Dimensions-Questionnaire, Rockwood Scale, Six-minute walking test, Medication, Heart failure medication with side effects, Lab (Hemoglobin, Hematocrit, Internatinal Normalized Ratio, Gamma-glutamyltransferase, Lactate dehydrogenase, C-reactive protein, Blood urea nitrogen, Creatinine, Glomerular filtration rate, Dialyse, Albumin, Total bilirubin, N-terminal pro brain natriuretic peptide, Potassium) Echocardiographie (left ventricular ejection fraction, left ventricular enddiastolic volume, left ventricular enddiastolic diameter, right ventricular ejection fraction, right ventricular enddiastolic diameter, tricuspid annular plane systolic excursion, right ventricular outflow tract, aortic valve insufficiency, mitral valve insufficiency, pulmonary valve insufficiency, tricuspid valve insufficiency, systolic pulmonary arterial pressure) Rehospitalization, Pump Parameter, Mean arterial pressure, Heart frequency, Weight

—

Countries

Germany

Contacts

Public ContactFelix Schönrath

Deutsches Herzzentrum Berlin

schoenrath@dhzb.de+493045932085

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026